id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0141-0008,FDA,FDA-2011-E-0141,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2024-03-13T12:14:04Z,,0,0,090000648119ca05
FDA-2011-E-0141-0007,FDA,FDA-2011-E-0141,U.S. Patent & Trademark Office to Johnson & Johnson - Letter,Other,Letter(s),2012-12-17T05:00:00Z,2012,12,2012-12-17T05:00:00Z,,2012-12-17T23:53:31Z,,0,0,0900006481190224
FDA-2011-E-0141-0006,FDA,FDA-2011-E-0141,Determination of Regulatory Review Period for Purposes of Patent Extension: LASTACAFT,Notice,General Notice,2012-05-03T04:00:00Z,2012,5,2012-05-03T04:00:00Z,,2012-05-03T16:16:35Z,2012-10694,0,0,0900006481004373
FDA-2011-E-0141-0005,FDA,FDA-2011-E-0141,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-04-17T04:00:00Z,2012,4,2012-04-17T04:00:00Z,,2024-03-13T11:45:08Z,,0,0,0900006480ff2440
FDA-2011-E-0141-0004,FDA,FDA-2011-E-0141,Letter to U. S. Patent & Trademark Office,Other,Letter(s),2012-01-10T05:00:00Z,2012,1,2012-01-10T05:00:00Z,,2024-03-13T12:32:04Z,,0,0,0900006480f91f53